In this section
@article{Jones:2025,
author = {Jones, EM and Sourij, C and Stradner, M and Schlenke, P and Sereban, N and Moser, O and Quinlan, R and Short, C-E and Harris, BHL and Fertleman, M and Taylor, GP and Oliver, N and Sourij, H and Dominguez-Villar, M},
journal = {European Journal of Immunology},
title = {IL-10- and IL-13-biased T cell responses to SARS-CoV-2 vaccination in diabetes},
year = {2025}
}
TY - JOUR
AB - Type 1 and type 2 diabetes are associated with increased severity and mortality from respiratory virus infections. Vaccination in the general population significantly reduces the risk of severe respiratory viral infection and triggers a strong, polyfunctional and lasting T cell response in healthy individuals. However, vaccine effectiveness in people with type 1 diabetes is unclear. Here we studied the magnitude and functional characteristics of vaccine-specific CD4+ and CD8+ T cell responses to vaccination in people with type 1 and type 2 diabetes and compared them to those of people living without diabetes, using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a model. We found defects in both CD4+ and CD8+ T cell memory maintenance and the functionality of the vaccine-specific T cells in people with diabetes compared to people without. In those individuals with type 1 and type 2 diabetes that harbored detectable vaccine-specific T cells, they displayed an unfocused, tolerogenic phenotype characterized by increased expression of IL-10 and IL-13 compared to people without diabetes. These results have implications for vaccination strategies for people with diabetes.
AU - Jones,EM
AU - Sourij,C
AU - Stradner,M
AU - Schlenke,P
AU - Sereban,N
AU - Moser,O
AU - Quinlan,R
AU - Short,C-E
AU - Harris,BHL
AU - Fertleman,M
AU - Taylor,GP
AU - Oliver,N
AU - Sourij,H
AU - Dominguez-Villar,M
PY - 2025///
SN - 0014-2980
TI - IL-10- and IL-13-biased T cell responses to SARS-CoV-2 vaccination in diabetes
T2 - European Journal of Immunology
ER -